Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.5. rezultāts no 100.
337. lappuse
... chromatography 130 Column chromatographic isomer content Copper content 22 Crystallinity 4 Cycloserine color assay 27 Daunorubicin potency ( special turbidimetric ) 19 Depressor substance test 40 Disc potency 52 Dissolution test 107 ...
... chromatography 130 Column chromatographic isomer content Copper content 22 Crystallinity 4 Cycloserine color assay 27 Daunorubicin potency ( special turbidimetric ) 19 Depressor substance test 40 Disc potency 52 Dissolution test 107 ...
351. lappuse
... chromatography . 436.304 Clindamycin phosphate vapor phase chromatography . 436.305 Thin layer chromatographic identity test for hetacillin . 436.306 Lincomycin gas liquid chroma- tography . 436.307 Spectinomycin vapor phase chroma ...
... chromatography . 436.304 Clindamycin phosphate vapor phase chromatography . 436.305 Thin layer chromatographic identity test for hetacillin . 436.306 Lincomycin gas liquid chroma- tography . 436.307 Spectinomycin vapor phase chroma ...
352. lappuse
... chromatographic identity 436.336 Thin layer chromatographic identity 436.344 Thin layer chromatographic identity free erythromycin content in erythro- mycin estolate bulk . 436.363 High - performance liquid chromatographic assay for ...
... chromatographic identity 436.336 Thin layer chromatographic identity 436.344 Thin layer chromatographic identity free erythromycin content in erythro- mycin estolate bulk . 436.363 High - performance liquid chromatographic assay for ...
393. lappuse
... chromatographic - grade water in a stoppered 2 - liter graduated cylinder . Dilute this entire solution in an appro- priate , suitably sized container with 4 liters of ultrapure deionized or high- performance liquid chromatographic ...
... chromatographic - grade water in a stoppered 2 - liter graduated cylinder . Dilute this entire solution in an appro- priate , suitably sized container with 4 liters of ultrapure deionized or high- performance liquid chromatographic ...
395. lappuse
... chromatographic assay . liquid ( a ) Equipment . A suitable high - per- formance liquid chromatograph equipped with : ( 1 ) A suitable detection system speci- fied in the monograph for the drug being tested ; ( 2 ) A suitable recording ...
... chromatographic assay . liquid ( a ) Equipment . A suitable high - per- formance liquid chromatograph equipped with : ( 1 ) A suitable detection system speci- fied in the monograph for the drug being tested ; ( 2 ) A suitable recording ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning